Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Societe Generale today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2300p (from 2200p).
Broker Forecasts data provided by www.sharesmagazine.co.uk